Home › Trials › NCT05797896

Observational study on geographic atrophy in age-related macular degeneration

A Multicentre, Natural History, Non-interventional Study Evaluating Biomarkers In Participants With Geographic Atrophy(GA) Secondary To Age-Related Macular Degeneration (AMD)

Observational Complement Therapeutics · NCT05797896

This study looks at how geographic atrophy from age-related macular degeneration changes over two years and whether certain proteins and genes can help us understand its progression better.

Quick facts

Study typeObservational
Enrollment250 (estimated)
Ages65 Years and up
SexAll
SponsorComplement Therapeutics Industry-sponsored
Locations22 sites (Glendale, California and 21 other locations)
Trial IDNCT05797896 on ClinicalTrials.gov

What this trial studies

This observational study aims to investigate the natural history of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) by assessing the relationships between circulating complement proteins, genetic profiles, and lesion progression over a 24-month period. Participants will undergo clinical evaluations and imaging to confirm their diagnosis and monitor changes in their condition. The study focuses on understanding biomarkers that may influence the progression of GA, providing insights into potential future treatments.

Who should consider this trial

Good fit: Ideal candidates are individuals aged 65 and older with a clinical diagnosis of bilateral geographic atrophy due to age-related macular degeneration.

Not a fit: Patients with a history of neovascular (wet) AMD or other significant ocular pathologies may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance understanding of geographic atrophy progression and lead to improved management strategies for patients with age-related macular degeneration.

How similar studies have performed: While this study focuses on a specific aspect of geographic atrophy, similar observational studies have shown promise in understanding AMD progression and biomarkers.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Clinical diagnosis of bilateral GA due to AMD as confirmed by fundoscopy and imaging at Screening
2. GA lesion sizes of ≥ 1.25 mm2 to ≤ 17 mm2 (approximately 1-7 disc diameters) in at least one eye as per Central Reading Center
3. Willing and able to provide written informed consent
4. Male or female aged 65 years and over

Exclusion Criteria:

1. History of neovascular (wet) AMD or presence of neovascular (wet) AMD in either eye confirmed by fundoscopy at screening and/or any pre-existing retinal imaging
2. History of intravitreal (IVT) injection in the study eye. Note: Intravitreal treatment with pegcetacoplan (Syfovre®) and avacincaptad pegol (IzervayTM) if approved within the participant's country of origin AND if deemed necessary by the Principal Investigator (PI) is allowed in the fellow eye only. IVT injections in the study eye are prohibited.
3. History of uveitis or endophthalmitis
4. High myopia (more than 6 diopter) in the study eye
5. Any ocular pathology which would impede clear imaging of the macula, e.g. intra-ocular opacities
6. Macular changes from causes other than AMD
7. Diabetic retinopathy in either eye. Note: Presence of systemic diabetes with no retinopathy is not exclusionary
8. Any other physical condition which would prevent the participant from undertaking imaging procedures
9. Any cell or gene therapy in either eye

Where this trial is running

Glendale, California and 21 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Dry Age-related Macular DegenerationGeographic AtrophyRetinal DiseaseMacular DegenerationMacular AtrophyRetinal DegenerationEye DiseasesAMD
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.